Arvinas

Arvinas is a dynamic biotechnology research company committed to pioneering advancements in targeted protein degradation therapeutics. Focused on improving the lives of patients affected by debilitating and life-threatening conditions, Arvinas is dedicated to the discovery, development, and potential commercialization of innovative therapies that degrade disease-causing proteins.

Arvinas utilizes its exclusive PROTAC® Discovery Engine platform to create proteolysis targeting chimeras, known as PROTAC® targeted protein degraders. These are engineered to leverage the body's natural protein disposal system, selectively and efficiently degrading and removing proteins that cause disease. Arvinas is strategically based at 395 Winchester Ave., 5 Science Park, New Haven, Connecticut 06511, US.

Currently, Arvinas is actively advancing multiple investigational drugs through clinical development programs. These include vepdegestrant, aimed at targeting estrogen receptors for patients with ER+/HER2- breast cancer; ARV-102, designed to target LRRK2 for neurodegenerative disorders; and ARV-393, which targets BCL6 for relapsed/refractory non-Hodgkin Lymphoma. We invite the management team at Arvinas to create a customized and exclusive company showcase and product listing on our platform.